Discovery founded through merger, combined biospecimen repository tops 10m

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Mergers and acquisitions, biospecimen, procurement, Life sciences companies, Life sciences, Investment

Four companies have merged under the name Discovery Life Sciences, joining forces to offer biospecimen analysis and procurement services.

Conversant Bio, Folio Bio, Legacy Discovery Life Sciences, and Phylogeny make up Discovery Life Sciences, a biospecimen analysis and procurement group for the pharmaceutical, biotechnology, and diagnostics industries.

The new company will leverage its respective consultative services along with a repository of more than 10m research-quality biospecimens—all available and processed for analysis.

Glenn Bilawsky CEO of Discovery told us, “We believe that our knowledge and innovative approach will accelerate the time from discovery through validation to commercialization of novel biomarkers, drug candidates, medical devices, and diagnostics.”

The company will focus on oncology, cardiology, neurology, as well as infectious, inflammatory, and autoimmune diseases.

Per the merger, the company’s newly combined catalog includes normal, suspect, and disease-state specimens. Including specimens of rare diseases and racially and ethnically diverse exemplars.

Discovery obtains these biosamples through its global, integrated network of more than 165 clinical sources, in 25 countries on six continents – Discovery Partners. Bilawsky said that these partners are “the route to hundreds of thousands of patients.”​ The company collaborates with a network of hospitals, medical centers, blood banks, clinical laboratories, and community-based medical practices.

The company stated that it can study specimens on all research and diagnostic platforms as an ISO 9001-certified company with CLIA-certified labs, IRB and Ethics Committee compliance, and all required EU approvals and certifications.

The merger was facilitated by Water Street Healthcare Partners, which also invested in the company.

Related news

Show more

Related products

show more

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Related suppliers

Follow us


View more